on demand webinar
The IVDR comes into effect on 5/25/2022 and provides new rules for homegrown tests (homebrew/LDTs)
Dr. Andreas Eckelt (IVDRconsulting)
Dr. Andreas Eckelt (IVDRconsulting)
• Ravindra Kolhe, MD, PhD • David Fabrizio, PhD • John Jiang, PhD • Yves Konigshofer, PhD
• available On Demand at genomeweb
• available On Demand at genomeweb
• Prognostication of Chronic Lymphocytic Leukemia (CLL) using NGS
• Evaluation of Strategies to Leverage NGS-based Minimal Residual Disease (MRD) in Multiple Myeloma (MM) and Acute Lymphoblastic Leukemia (ALL)
• Evaluation of Strategies to Leverage NGS-based Minimal Residual Disease (MRD) in Multiple Myeloma (MM) and Acute Lymphoblastic Leukemia (ALL)
Video recording of the lecture:
- Tumor Profiling - Liquid Biopsy -Immuno-Oncology
- Tumor Profiling - Liquid Biopsy -Immuno-Oncology
in Chronic Lymphocytic Leukemia in the Era of High-Throughput Sequencing
In this presentation, Ms. Krystyna Nahlik, PhD will present studies on the impact of reference materials on the limit of detection (LoD) and sensitivity in liquid biopsy testing:
- Seraseq® ctDNA Complete
- Seraseq® ctDNA v2
- Seraseq® ctDNA MRD panel
- Seraseq® ctDNA Complete
- Seraseq® ctDNA v2
- Seraseq® ctDNA MRD panel
Practical example from the